Navigation Links
NxStage® Enters Into New Lease for Corporate Headquarters Within Lawrence, MA

LAWRENCE, Mass., June 29, 2011 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, announced that it has entered into a new 11-year lease agreement with 350 Riverwalk LLC to move its corporate headquarters to the revitalized historic mill complex on the River Walk Campus at 350 Merrimack Street, Lawrence, MA.  The move, which is expected to be completed in mid-2012, reaffirms NxStage's over ten year commitment to Lawrence, MA and the Greater Merrimack Valley community since 2001.  


The revitalized mill space is in a more central location and is expected to allow the Company's customers, partners and employees easier access to the office and many local amenities.

"We've built a unique and innovative culture at NxStage," said Jeffrey Burbank, Chief Executive Officer, NxStage Medical, Inc.  "We've had a great experience in Lawrence and we're proud to contribute to the area's growth and vitality."  

"NxStage Medical has been a welcome employer and corporate citizen in the Fifth District, and their decision to stay and grow in Lawrence will continue to benefit the economic development and revitalization of the City," said Congresswoman Niki Tsongas (D-MA). "Given the importance of the medical technology industry to Massachusetts, innovative employers like NxStage help to ensure the presence of good jobs in our community and I wish them continued success in the years ahead."

"NxStage's move to the revitalized Riverwalk Properties is one of the most exciting additions to our complex to date," said Sal Lupoli, President/CEO of 350 Riverwalk LLC.  "I am extremely proud NxStage will be joining our complex."

Located in the heart of the Merrimack Valley, the Riverwalk Properties consists of five separate buildings creating a unique campus style business environment.  The campus features easy access to public transportation and a friendly, collaborative and professional environment. Riverwalk Properties has a diverse group of corporate tenants, a number of which are in the health care industry.

About NxStage

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contacts:  
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.  

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
2. First NxStage® Home Hemodialysis Patients Celebrate Seven-Year Anniversary
3. NxStage® Appoints Nancy J. Ham to Its Board of Directors and Announces Resignation of Board Member Jonathan T. Silverstein
4. NxStage® to Report Fourth Quarter and Full Year 2010 Financial Results
5. NxStage® Reports Fourth Quarter and Full-Year 2010 Financial Results; Revenue Growth Exceeds Company Guidance
6. In Celebration of the 31st Annual Dialysis Conference, NxStage® Announces Over 5,000 Patients Using the System One™ for Home Hemodialysis
7. New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period
8. NxStage® to Report First Quarter Fiscal 2011 Financial Results
9. NxStage® Names Michael Miller, Jr. President, International
10. Chronic Disease Research Group Study Shows Daily Home Hemodialysis Therapy with the NxStage® System One™ is Associated with Lower Risk of Mortality and Higher Survival Estimates Compared to Conventional Thrice-Weekly Dialysis
11. NxStage® Advances Global Growth Strategy with System One™ Regulatory Approval and Distribution Agreement in Australia and New Zealand
Post Your Comments:
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... has found that immunotherapy can be efficiently ...
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is donating ... Beat ” campaign. The partnership between the two groups began in 2014 with Vitalalert ... cause. , MAP International was founded in 1954 and is an international Christian-based health ...
(Date:11/25/2015)... ... 2015 , ... Dental professionals who would like to become more proficient on ... Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on ... co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to ...
(Date:11/25/2015)... ... 2015 , ... The McHenry County law firm of Botto Gilbert Lancaster, ... Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant ... (2d) 130884WC. , According to court documents, Adcock testified that on May 10, 2010 ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, ... facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion ... at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for ...
(Date:11/25/2015)... ... 25, 2015 , ... In an ongoing Clinical Study conducted by an independent ... UV Angel is evaluating the efficacy of its product and its disinfection protocol. This ... beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical center ...
Breaking Medicine News(10 mins):